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Abstract
Combinations of direct-acting anti-virals offer the potential to improve the efficacy, tolerability and duration of the current
treatment regimen for hepatitis C virus (HCV) infection. Viral entry represents a distinct therapeutic target that has been
validated clinically for a number of pathogenic viruses. To discover novel inhibitors of HCV entry, we conducted a high
throughput screen of a proprietary small-molecule compound library using HCV pseudoviral particle (HCVpp) technology.
We independently discovered and optimized a series of 1,3,5-triazine compounds that are potent, selective and non-
cytotoxic inhibitors of HCV entry. Representative compounds fully suppress both cell-free virus and cell-to-cell spread of
HCV in vitro. We demonstrate, for the first time, that long term treatment of an HCV cell culture with a potent entry inhibitor
promotes sustained viral clearance in vitro. We have confirmed that a single amino acid variant, V719G, in the
transmembrane domain of E2 is sufficient to confer resistance to multiple compounds from the triazine series. Resistance
studies were extended by evaluating both the fusogenic properties and growth kinetics of drug-induced and natural amino
acid variants in the HCVpp and HCV cell culture assays. Our results indicate that amino acid variations at position 719 incur
a significant fitness penalty. Introduction of I719 into a genotype 1b envelope sequence did not affect HCV entry; however,
the overall level of HCV replication was reduced compared to the parental genotype 1b/2a HCV strain. Consistent with these
findings, I719 represents a significant fraction of the naturally occurring genotype 1b sequences. Importantly, I719, the most
relevant natural polymorphism, did not significantly alter the susceptibility of HCV to the triazine compounds. The
preclinical properties of these triazine compounds support further investigation of entry inhibitors as a potential novel
therapy for HCV infection.
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Introduction
An estimated 180 million people worldwide are infected with
hepatitis C virus (HCV) and are at risk of developing severe and
potentially life-threatening liver diseases, including chronic
hepatitis, cirrhosis and hepatocellular carcinoma. For the past
decade, the combination of pegylated interferon-alpha and
ribavirin has served as the standard of care (SOC) for the
treatment of HCV infection [1,2]. These therapies exhibit limited
efficacy against strains commonly found in the United States and
Europe and are associated with significant toxicities [1,2]. In 2011,
two small-molecule inhibitors of the HCV NS3/4a serine
protease, Victrelis
TM/boceprevir (Merck) and Incivek
TM/telapre-
vir (Vertex), received regulatory approval for the treatment of
HCV infection. In pivotal phase 3 clinical trials, addition of either
agent to the combination of pegylated interferon-alpha and
ribavirin significantly improved sustained virologic response
(SVR) rates and reduced the duration of therapy for many HCV
patients [3–6]. Despite the recent paradigm shift in HCV therapy,
first generation protease inhibitors suffer from significant draw-
backs, including the introduction of additional toxicities, in-
convenient dosing regimens and documented viral resistance. In
addition to these concerns, there continues to be an urgent need to
replace pegylated interferon-alpha and ribavirin with novel direct
acting anti-virals to drive further improvements in the efficacy,
tolerability and duration of HCV therapy.
In light of these considerations, it is crucial that future efforts
focus on the development of a wider repertoire of anti-viral agents,
including inhibitors with novel mechanisms of action. Viral entry
represents an attractive treatment class for HCV and has been
validated clinically for a number of human pathogenic viruses.
HCV entry is mediated by two viral envelope glycoproteins, E1
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CD81 [7,8], the scavenger receptor class B type 1 (SR-B1) [9,10],
the Niemann-Pick C1-like 1 cholesterol absorption receptor
(NPC1L1) [11] and the tight junction proteins claudin-1 [12]
and occludin [13]. The mechanism of HCV attachment to the
host target cell is poorly characterized and may involve binding to
glycosaminoglycans and/or the LDL receptor [14–16]. Alterna-
tively, initial binding of virus/lipoprotein complexes to SR-B1 may
prime interactions with the other co-receptors [17]. Following
virus attachment, HCV particles recruit CD81/claudin-1/occlu-
din complexes through a poorly defined process. Interactions with
SR-B1 and CD81 are likely mediated by E2 [10,18–21]. In
contrast, direct binding between the viral envelope glycoproteins
and the tight junction proteins, claudin-1 and occludin, has not
been established [12,22]. Indeed, recent evidence suggests that the
interaction between the HCV envelope and claudin-1 is indirectly
mediated by CD81 [23] and may be regulated via receptor
tyrosine kinase activity [24]. The requirement for sequential
interactions between the viral envelope and key host receptors/co-
receptors may provide new drug targets that could be exploited by
small-molecule inhibitors.
After attachment and co-receptor recruitment, HCV is in-
ternalized by receptor-mediated endocytosis via clathrin-coated pits
into mildly acidic endosomes [25]. The pH-dependence for HCV
entry has been well characterized in the HCVpp and HCV cell
culture systems with inhibitors that specifically block endosome
acidification [7,26,27]. By analogy to other closely-related viruses,
co-receptor binding and the acidic pH environment of the
endosome drive multiple conformational changes that convert the
envelope from a metastable state to a lower energy state [28–30].
These structural changes result in the exposure of a buried
hydrophobic fusion loop which inserts into the host membrane
and drives the fusion of the viral envelope with the host membrane,
resulting in the delivery of the core particle into the cytoplasm.
Compoundsthatinhibitkeyintra-orinter-molecularinteractionsor
stabilizeintermediateconformationsintheHCVenvelopemayalso
have the potential to block key HCV fusion processes.
To discover novel small-molecule inhibitors of HCV entry, we
optimized and validated an HCVpp-based entry assay for high
throughput screening and successfully completed a hit finding
campaign of a random library of diversified drug-like compounds.
Our screening strategy yielded multiple hit compounds, represent-
ing different chemotypes. Chemical optimization of one series led
to the discovery of several potent, selective and non-cytotoxic
1,3,5-triazine inhibitors of HCV entry that block both cell-free and
cell-cell modes of transmission [31]. Subsequently, a similar series
Figure 1. Structure and anti-viral activity of PRO037115. (A, left panel) Generic structure representing the N2-R1-phenyl-N4-R2-6-R3-2,4-
diamine-1,3,5-triazine lead series of HCV entry inhibitors. (A, right panel) The structure of PRO0371155. (B, left panel) HCVpp pseudotyped with the
GT1a envelope were added to Hep3B cells in the presence of various concentrations of PRO0371155. Luciferase activity was measured 72 hrs post-
infection using BrightGlo reagent (Promega) as described in the Materials and Methods. The mean EC50 across three independent assays was 2 nM.
(B, right panel) PRO0371155 was tested for its inhibitory activity against GT 1a/2a HCV as described in the Materials and Methods. PRO0371155




PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35351of triazine-based entry inhibitors was reported by a group at
Bristol-Myers Squibb [32].
We demonstrate, for the first time, that long-term treatment
with an entry inhibitor perturbs normal viral dynamics in culture
and leads to complete viral clearance of HCV in vitro. We also
provide an independent confirmation that a single amino acid
variation, V719G, in the transmembrane domain of E2 is
sufficient to confer resistance to representative compounds from
the triazine series [32]. We have extended these findings by
evaluating the fusogenic properties and kinetics of both drug-
induced and natural polymorphisms in both the HCVpp and cell
culture assays. We show that, isoleucine, the most common natural
polymorphism at position 719, does not significantly alter the
susceptibility of HCV genotype 1 to triazine compounds. The
results indicate that there is a significant fitness cost associated with
amino acid variation at position 719 and provide a rationale for
the low frequency of pre-existing drug resistant variants in the
natural HCV genotype 1 population. Taken together, our data
support further investigation of entry inhibitors, including
triazines, as a potential therapy for HCV infection.
Materials and Methods
HCV pseudoviral particle (HCVpp) entry assay
HCVppweregeneratedin293Tcellsasdescribedpreviously[7].
Fusogenic envelopes representing different genotypes were isolated
and cloned from HCV+ patient sera as described elsewhere [33].
Culture supernatants were harvested 48 h post-transfection and
clarified by centrifugation to remove cell debris. The infectivity of
the viral supernatants was determined by serial dilution followed by
infection of Hep3B cells. The Hep3B (HB-8064) and 293T (CRL-
11268) cell lines were obtained from ATCC.
HCVpp assays were conducted essentially as described pre-
viously [7]. Briefly, Hep3B target cells were plated in 384-well
microtiter plates (2,000 cells/well). Test inhibitor compounds were
diluted stepwise into the assay medium to the specified final
concentration (final DMSO concentration of 0.5%). Diluted virus
stock (,100,000 Relative Light Unit, R.L.U. equivalent) was
added and the plates were incubated at 37uC for 72 h. Entry
activity was determined using BrightGlo reagent according to the
manufacturer’s instructions (Promega).
Isolation and cloning of fusogenic envelopes from HCV+
patient sera
Genotype specific primers and nested RT-PCR were used to
amplify the E1/E2 coding sequence from the sera of individuals
infected with different HCV 1a, 1b, 2a and 2b strains as described
elsewhere [33]. Briefly, viral RNA was isolated from 150 mLo f
infected patient serum using the QIAamp Viral RNA mini Kit
(QIAGEN). Viral RNA was then reverse transcribed using the
SuperScript
TM III First-Strand Synthesis System for RT-PCR
(Invitrogen). The resulting DNA served as template for a first
round of amplification with genotype-specific outer primers
followed by a second round of amplification with genotype-
specific inner primers. The forward inner primer sequence was
designed to allow directional cloning of nucleic acids encoding
HCV E1/E2 glycoproteins into the pcDNA3.1 TOPO vector
(Invitrogen). The forward inner primer also contained a consensus
Kozak sequence to direct expression of the envelope glycoproteins.
Both rounds of amplification were performed with high fidelity
Platinum Pfx DNA polymerase (Invitrogen).
DNA sequences encompassing amino acid residues 171–758 of
the HCV polyprotein from genotypes 3, 4, and 6 were synthesized
at Bio Basic Inc. (Markham, Canada) and cloned into the HindIII
and XbaI sites of the pcDNA3.1 (Invitrogen) expression vector
under the control of a CMV promoter. DNA sequences were
previously described and are as follows: Genotype 3, UKN3A1.9
(AY734985), Genotype 4, UKN4.11.1 (AY734986), and Genotype
6 UKN6.5.340 (AY736194) [33].
HCV cell culture
Establishment of replicating chimeric HCV genotype 1/2a cell
cultures was as described elsewhere: GT 1a/2a HCV [34] and GT
1b/2a HCV [35]. Templates for in vitro transcription of HCV
reporter virus RNAs were designed and synthesized. Large scale
RNA synthesis was performed with linearized plasmids using the
RiboMAXLargeScaleRNAProductionSystemasdescribedinthe
manufacturer’s instructions (Promega). After RNA synthesis and
removal of the DNA template, viral RNA was purified using the
RNeasy Midi kit as per the manufacturer’s instructions (Qiagen).
To establish a replicating HCV culture, sub-confluent human
hepatoma-derived target cells obtained from Dr. F. Chisari (TSRI)
[36], were resuspended in ice-cold PBS (6610
6 cells), mixed with
in vitro transcribed HCV RNA and subjected to electroporation as
previously described [34,35]. Cell cultures were maintained at sub-
confluent levels by passaging the cells every 3–4 days. At various
days post-transfection, HCV particles from culture supernatants
were harvested and clarified by centrifugation. Infection of naı ¨ve
hepatoma target cells by cell culture-derived HCV was determined
using the Renilla luciferase assay system according to the
manufacturer’s instructions (Promega).
HCV viral spread assay
An assay capable of measuring both cell-free and cell-cell
transmission of HCV was established based on previously
published methods [37]. To evaluate cell-cell and cell-free spread
of GT 1a/2a HCV, infected cells (90% HCV+) were stained with
CMFDA green, according to the manufacturer’s instructions
Table 1. Various triazine compounds exhibit broad activity against HCV genotype 1a and 1b strains.
Cmpd. ID HCVpp Median EC50 (nM) HCV Cell Culture EC50 (nM) VSVpp EC50 (nM) Hep3B CC50 (nM)
GT 1a GT 1b GT 1a/2a GT 1b/2a
PRO0371155 9 (n=21) .825 (n=12) 9 .1,000 39,000 31,000
PRO0373192 9 (n=18) 10 (n=17) 11 18 26,357 25,296
PRO0502661 8 (n=19) 4 (n=19) 9 12 .100,000 .100,000
PRO0502647 11 (n=22) 3 (n=17) 5 3 .100,000 .100,000
PRO0502797 13 (n=19) 5 (n=17) 17 11 .100,000 .100,000
doi:10.1371/journal.pone.0035351.t001
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cells. Mixed infected and naı ¨ve cells (7.5610
5) were seeded in T-75
flasks and subjected to treatment with 1 mM of a representative
entry inhibitor or DMSO vehicle for 72 h at 37uC. As a positive
control for cell-cell transmission, PA-25, a mouse monoclonal
antibody raised against sE2 (sE2 was obtained from Austral
Biologicals) was also tested in the viral spread assay. PA-25 was
used at a concentration of 10 mg/mL, approximately 20-fold
above its EC50 concentration against GT1a/2a HCV
(EC50=0.5 mg/mL). Cells were detached from tissue culture
flasks, washed 26 with PBS, fixed and permeabilized with BD
Cytofix/cytoperm (BD Biosciences). Infected cells were stained
with 10 mg/mL anti-NS3 antibody 1847 (Virostat) or mIgG1 (BD
Biosciences) and counter-stained with 1 mg/mL AlexFluor 647
(Invitrogen). Single- and dual-labeled cells were quantified by flow
cytometry in a FACSCalibur (BD Biosciences) and the data were
analyzed using FlowJo v. 8.8.7 software (TreeStar). Long term
treatment and drug resistance studies were conducted essentially as
described above. Infected cell cultures (10%, 20%, 33%, 90%
HCV+) were established and split every 3 days to maintain sub-
confluent levels. The change in HCV+ cells, in the presence of test
inhibitors or the vehicle control (DMSO), was determined every 3
days by flow cytometry as described above.
Quantification of HCV RNA
Quantitative real-time RT-PCR assays were used to determine
the abundance of viral RNA in transfected cells. Total RNA was
isolated from cell lysates using the RNeasy kit (Qiagen) in
accordance with the manufacturer’s instructions. RNA was
isolated from cell culture supernatants using the QIAamp Viral
RNA kit (Qiagen). Quantitative TaqMan RT-PCR analysis was
carried out using primer pairs and a probe targeting a conserved
59-base sequence within the 59 nontranslated RNA segment of the
genome: HCV19FP, CGACACTCCGCCATGAATC;
HCV19RP, GCGCTTTCTGCGTGAAGAC; and HCV16
NED/MGB, NED-CCCCTGTGAGGAACTA-MGB. TaqMan
assays used reagents provided with the EZ RT-PCR Core Reagent
kit (Applied Biosystems) and an ABI Prism 7700 instrument.
Reactions (20 mL) were incubated at 50uC for 2 min, 60uC for
45 min, and 95uC for 5 min, followed by 40 cycles of 95uC for
20 sec and 60uC for 1 min.
Results
Discovery of novel inhibitors of HCV entry
We optimized and validated an HCV entry assay for high
throughput screening (HTS) and completed a hit finding campaign
against a library of .370,000 proprietary drug-like compounds.
Our screening strategy yielded multiple potent and selective hit
compounds representing different chemotypes. A chemical optimi-
zation program led to the independent discovery of a series of novel
inhibitors of HCV entry, represented by the generic 1,3,5-triazine
structure depicted in Figure 1A [31]. A similar series of triazine
inhibitors of HCV entry was recently discovered by Baldick and co-
workers and published elsewhere [32].
To investigate the anti-viral properties of this series of triazines,
variousconcentrationsofrepresentativecompoundswereevaluated
fortheirabilitytoblockentryofHCVppintoHep3Bcells.Thedose
response curve shown in Figure 1B represents a composite of 3
independent assays. PRO0371155 (structure shown in Figure 1A)
exhibitedpotentactivityagainst aprototypicalgenotype1astrainin
the HCVpp assay with an EC50=2 nM. In contrast, PRO0371155
didnotinhibittheentryofpseudoviralparticlescomplementedwith
the envelope glycoproteins from irrelevant viruses including VSV
(shown in Table 1). Moreover, PRO0371155 demonstrated
minimal cytotoxicity against a panel of cell lines and primary cells
(Hep3B; Table 1, Huh-7, 293T, HeLa, Daudi, Ramos, Jurkat,
primary hepatocyte; data not shown) in the CellTiter Glo assay,
indicating the potential for a large therapeutic index. Taken
together, these results suggest that PRO0371155 blocks a key step
Figure 2. Spectrum of activity of representative triazines
against envelopes isolated from HCV
+ patient sera. HCV RNA
was isolated and purified from sera obtained from individuals infected
with different strains of HCV, representing genotypes 1a, 1b, 2a, 2b.
Envelopes representing genotypes 3, 4, and 6 were described in the
Materials and Methods and published elsewhere [33]. Genotype specific
primers were used to amplify sequences encoding the E1/E2
glycoprotein from each of the strains by RT-PCR. Envelope sequences
were ligated into expression constructs as described in the Materials
and Methods. Unique HCVpp, representing different genotypes, were
produced in 293T cells and validated with the anti-CD81 mAb, JS-81.
Individual HCVpp were normalized based on total infectivity and added
to Hep3B cells in the presence of various concentrations of PRO0371155
(Panel A) or PRO0502797 (Panel B) in 384-well microplates. Luciferase
activity was measured 72 hrs post-infection using Bright Glo reagent
(Promega). The potency of PRO0371155 and PRO0502797 against each
fusogenic envelope was expressed as a mean EC50. Each data point
represents the average of multiple dose response experiments (n.3).
The genotype specific panel consisted of the following strains:
genotype 1a (n=22), genotype 1b (n=19), genotype 2a (n=2),
genotype 2b (n=1), genotype 3, (n=1), genotype 4, n=1), genotype
6 (n=1). Actual number of strains tested for each compound is
summarized in Table 1. The box extends from the 25
th to the 75
th
percentile, with a line at the median EC50. The whiskers mark the full
range from the lowest to the highest EC50.
doi:10.1371/journal.pone.0035351.g002
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rather than a non-specific host function.
The breadth of anti-viral activity of PRO0371155 was assessed
in the HCVpp assay against a novel panel of fusogenic envelopes
representing different genotypes. The panel consisted of envelopes
from 40 unique genotype 1 strains as well as 7 strains representing
genotypes 2a, 2b, 3, 4 and 6. PRO0371155 exhibited potent and
specific inhibition of all twenty-one genotype 1a strains tested with
a median EC50=9 nM (Figure 2A and Table 1). In contrast,
PRO0371155 exhibited limited activity against genotype 1b
(median EC50.825 nM; n=12 strains) and genotype 4 strains
(EC50=190 nM; n=1 strain) (Figure 2A and Table 1) and no
activity against HCVpp typed with envelopes representing
genotypes 2a, 2b, 3, and 6 (EC50.1000 nM). Further chemical
modification of the triazine series led to a sub-series of inhibitors
that possess broad and potent activity against genotype 1a and 1b
HCV strains, summarized in Table 1. A comparison of the
genotype spectrum of PRO0371155 with PRO0502797 (Figure 2A
and 2B) demonstrates a significant shift in terms of breadth of
activity and potency across multiple genotype 1b strains in this
sub-series. PRO0502797 maintained excellent activity against
genotype 1a strains (median EC50=13 nM; n=19 strains) while
exhibiting potent activity against genotype 1b (median
EC50=5 nM; n=17 strains) (summarized in Table 1).
PRO0502797 exhibited no activity against genotypes 2–6 in the
HCVpp assay (Figure 2B). This high degree of specificity for HCV
genotype 1 was also observed for a similar series of triazines [32]
The anti-viral activity and genotype specificity of the lead
compounds were confirmed and extended in an authentic HCV
replication assay [34]. Viral supernatants were harvested from
producerculturesandusedtoinfectnaı ¨vetargetcellsinthepresence
of various concentrations of entry inhibitors. As observed in the
HCVpp assay, PRO0371155 demonstrated potent anti-viral
activity against GT 1a/2a HCV in culture with an EC50=9nM
(shown in Figure 1B) and no anti-viral activity against GT 1b/2a
HCV(summarizedinTable1)atthehighestconcentrationtested.A
sub-series of lead compounds, exemplified by PRO0502797, were
Figure 3. PRO0371155 inhibits HCV infection by both cell-free and cell-cell modes of transmission. The anti-viral activity of PRO0371155
was evaluated in an assay that measures both cell-free and cell-cell transmission of virus [37]. To evaluate transmission of GT 1a/2a HCV in culture,
infected cells (90% HCV+) were stained with CMFDA green, according to the manufacturer’s instructions (Invitrogen), and mixed at a ratio of 5:1 with
non-stained naı ¨ve cells. Mixed infected and naı ¨ve cells (7.5610
5 total) were seeded in T-75 flasks and subjected to treatment with 1 mMo f
PRO0371155 or DMSO vehicle for 72 h at 37uC. As a positive control for cell-cell transmission, PA-25, a mouse monoclonal antibody raised against sE2
was also evaluated in the viral spread assay at a single concentration of 10 mg/mL. This concentration is approximately 20-fold above its EC50
concentration and is sufficient to completely inhibit HCV entry in a single-cycle infection assay. Cells were detached, fixed and permeabilized withB D
Cytofix/cytoperm (BD Biosciences). Infected cells were stained with anti-NS3 antibody 1847 (Virostat) or mIgG1 (BD Biosciences) and counter-stained
with 1 mg/mL AlexFluor 647 (Invitrogen). Single- and dual-labeled cells were quantified by flow cytometry.
doi:10.1371/journal.pone.0035351.g003
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representing both genotypes 1a and 1b (summarized in Table 1).
Recent studies have suggested that HCV can spread in culture
by both cell-free virus (de novo) and cell-to-cell transmission [37,38].
To determine whether the triazine series can block both routes of
infection, we utilized a flow cytometry-based cell-to-cell trans-
mission assay [37]. Infected cells, stained with CellTracker green,
were mixed with naı ¨ve cells in the presence or absence of entry
inhibitors. After staining with anti-NS3 specific mAbs, newly
infected cells appear as a population of singly stained cells (red)
localized to the lower right quadrant in each panel shown in
Figure 3. Treatment of cultures with neutralizing concentrations of
the anti-E2 monoclonal antibody, PA-25, reduced but did not
eliminate viral transmission (Figure 3, compare 18.3% to 5.8%
HCV+ cells in the PA-25 and DMSO control, respectively). In the
presence of PRO0371155, however, viral spread was reduced to
background levels, demonstrating a complete block in both cell-
free and cell-cell viral transmission (Figure 3, compare HCV+ cells
in the lower right quadrants between PRO0371155 (0.48%) and
Background (0.31%)).
Long term treatment in vitro with a representative
triazine compound
Small-molecule inhibitors that target the HCV NS3 protease or
NS5B polymerase have been shown to clear HCV replicons from
permissive cell lines [39,40]. To test whether an HCV entry
inhibitor could promote viral clearance in vitro, we developed a long
term viral replication assay using cell culture derived GT 1a/2a
HCV. The percentage of infected hepatocytes in HCV+ patients is
estimated to be around 5–20% [41–43]. We established several
HCV cell cultures that approximated this estimated value: 10%,
20%, 33% and 90%, as determined by NS3 staining. Infected
cultures were passaged in the presence of PRO0371155 (,606
EC50) or vehicle control, stained with anti-NS3 antibodies and
analyzed by flow cytometry. In the most stringent example,
infected cells treated with PRO0371155 were eradicated from
a culture that was initially 90% HCV+, but not in the passage
control treated with DMSO (Figure 4A). At day 116, the drug
pressure was released and the cultures were passaged for an
additional 30 days in the absence of PRO0371155 (see arrow in
Figure 4A). Viral rebound was not observed during the washout
period, indicating that the cell cultures had been completely
cleared of replicating HCV (Figure 4A).
Results obtained in the flow cytometry based assay were
confirmed and extended by quantitative analysis of HCV RNA
(Figure 4B). After 100 days in the presence of PRO0371155 in cell
cultures, HCV RNA levels were reduced to the limit of
quantification in our assay (,0.5 copies/cell), as determined by
serial dilution. Following removal of PRO0371155, HCV RNA
was maintained at background levels for .50 days in culture,
Figure 4. Long term treatment of HCV infected cell cultures with a triazine compound promotes viral clearance. PRO0371155 was
evaluated for its inhibitory activity against GT 1a/2a HCV over multiple weeks in culture. (A) Cell cultures were ,90% infected with cell culture-derived
GT 1a/2a HCV. Cultures were treated with 1 mM PRO0371155 or DMSO in the passage control. At 3–4 day intervals, cells were subjected to staining
with anti-NS3 antibodies and analysis by flow cytometry as described in the Materials and Methods. The percentage of HCV+ cells as a function of
time was plotted for each experiment. (B) Results obtained in the protein expression analysis were confirmed and extended by qRT-PCR analysis of
HCV RNA isolated from HCV infected cultures treated with PRO0371155 or DMSO control at various time points. HCV RNA was normalized to GAPDH
mRNA and expressed in copies/cell. The limit of quantification of the qRT-PCR assay was found to be ,0.5 copies/cell. (C) Cell cultures were ,20%
infected with cell culture-derived GT 1a/2a HCV. Cultures were treated with 1 mM PRO0371155, 10 IU/mL IFN-alpha (Sigma) or DMSO in the passage
control. At 3–4 day intervals, cells were subjected to staining with anti-NS3 antibodies and analysis by flow cytometry as described in the Materials
and Methods. The percentage of HCV+ cells as a function of time was plotted for each experiment. (D) Data shown in panel C were re-plotted on
a different scale to accentuate the differences between IFN-alpha and PRO0371155 treated HCV+ cultures.
doi:10.1371/journal.pone.0035351.g004
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expression studies (Figure 4A). Our results suggest that mainte-
nance of an infected cell culture requires multiple rounds of
infection to counterbalance the loss of infected cells due to virus-
induced cell death [44,45]. Moreover, these results imply that
entry inhibitors have the potential to contribute to the eradication
of viral infection in vivo.
A second HCV cell culture was established where 20% of the
cells were HCV+ at baseline. As expected, exposure of this culture
to IFN-alpha resulted in a rapid and pronounced loss of NS3
staining (Figure 4C). In contrast, PRO0371155 treatment resulted
in a more gradual decline in the percentage of HCV+ cells
(Figure 4C), while viral spread rapidly occurred in the vehicle-
treated control culture. The data for IFN-alpha and
PRO0371155, re-plotted using a different y-axis scale to
accentuate the different kinetics, is shown in Figure 4D. The
half-life of the infected cells ranged from between 5 days (20%
HCV+ culture) to 20 days (90% HCV+ culture) which is in range
with the 1.7–70 days initially estimated by modeling of HCV viral
dynamics in vivo [46].
Drug resistance studies with PRO0371155
In our long term treatment studies, only one of four drug-
treated cultures developed resistance to PRO0371155. In this
culture, 33% of the cells were initially HCV positive by NS3
staining (Figure 5, day 0). In the passage control culture (DMSO),
HCV rapidly spread throughout the culture to infect .90% of the
total cells (Figure 5, day 14). In contrast, the percentage of infected
cells in the PRO0371155-treated culture dropped rapidly, to near
background levels, over 14 days of drug exposure. At day 21, viral
breakthrough was observed in the presence of PRO0371155
(Figure 5) and eventually reached levels that were comparable to
the untreated passage control culture (Figure 5). In this culture,
loss of viral suppression and the emergence of drug resistance
required ,3 weeks, indicating a relatively moderate barrier to
resistance in vitro (Figure 5).
ViralsequencesencodingtheE1/E2envelopeglycoproteinswere
isolated from day 42 cell cultures, cloned and sequenced. A single
amino acid change, V719G, localized to the N-terminal region of
the transmembrane domain of the E2 glycoprotein was found to be
sufficient to confer resistance to PRO0371155 in the HCVpp assay
(Table 2). Substitution of V719 with a glycine residue resulted in
a .500-fold loss in susceptibility to PRO0371155 in the HCVpp
assay (Table 2, compare EC50=2 nM vs. EC50.1,000 nM). The
V719G substitution had a similar .200-fold reduction on the
susceptibility of HCVpp to PRO0502797, a more broadly active
triazine inhibitor (Table 2). We have also conducted a drug
resistancestudywithPRO0502797andhaveidentifiedtheidentical
V719G substitution as the major determinant of resistance. Genetic
drift present in the culture prior to compound addition did not
contribute to PRO0371155 resistance (Table 2, compare parent
GT1a envelope with that of the GT1a passage control). A second
amino acid change, T388A, was identified in the drug treated
cultures. This variant, which localized to the E1 glycoprotein, did
not have any influence on susceptibility to PRO0371155 in the
HCVpp assay (Table 2). Our findings, using novel triazine
inhibitors, provide an independent confirmation that V719G is
the major determinant of resistance to the triazine series of HCV
entry inhibitors [32].
Fusogenic properties and growth kinetics of natural and
drug-induced polymorphisms
An analysis of non-redundant HCV envelope sequences in the
public database revealed that V719 is relatively well conserved
(,85%) across all genotypes [32]. Three natural polymorphisms,
however, were identified at position 719, including: isoleucine
(14%), leucine (,1%) and alanine (,1%) [32]. To evaluate the
fusogenic properties of the potential variant envelopes, individual
amino acid variants (V719G, V719I, V719L, and V719A) were
introduced into a genotype 1a or genotype 1b background by site-
directed mutagenesis. HCVpp, representing each potential poly-
morphismatposition719,wereproducedin293Tcellsasdescribed
in the Materials and Methods, and entry activity was quantified in
Hep3B cells. Luciferase activity was normalized to p24 content in
the viral supernatants and expressed as R.L.U./ng p24 (Figure 6).
Introduction of the V719L amino acid variant into a genotype
1a background had no effect on HCVpp entry, while the V719G
drug-induced variant exhibited a modest 1.5-fold reduction in
entry activity compared to the parental GT 1a strain (Figure 6,
compare GT 1a with GT 1a-V719L and GT 1a-V719G). In
contrast to these results, GT 1a-V719I exhibited a 30-fold
reduction in HCV entry activity (Figure 6, compare GT 1a with
GT 1a-V719I). Surprisingly, the opposite pattern was observed
after identical substitutions were introduced into the GT 1b
background. In this case, introduction of V719G and V719L
resulted in a 5- and 30-fold reduction in HCV entry activity
compared to the parental GT 1b strain, respectively (Figure 6,
compare GT 1b with GT 1b-V719G and GT 1b-V719L), whereas
the V719I substitution resulted in a modest 1.5-fold enhancement
of entry (Figure 6, compare GT 1b with GT 1b-V719I). In
agreement with these findings, I719 represents a significant
fraction (21%; total of n=438 non-redundant sequences) of
genotype 1b sequences in the public database and is identified in
only a small fraction of genotype 1a sequences (0.9%; total of
n=797 non-redundant sequences) [47].
Other polymorphisms were found to be extremely rare: L719
(GT 1a: 0.1%; n=797 and GT 1b: 0%; n=438) and both G719
and A719 were not found in our survey of 1,235 genotype 1
sequences in the database [47]. The entry properties of each of the
potential polymorphisms at position 719 partly explain the
frequency of occurrence in the natural HCV genotype 1
population (Figure 6). However, the relatively high levels of
HCVpp entry activity observed for the V719G, V719L, V719A
variants in the GT 1a background and V719A in the GT 1b
background (see Figure 6) did not correlate with their low
Figure 5. Selection of viral variants with reduced susceptibility
to triazines. Cell cultures that were ,30% infected with cell culture-
derived GT 1a/2a HCV were established and treated with 1 mM
PRO0371155 or DMSO in the passage control. Cultures were split twice
weekly to maintain sub-confluent levels. The percentage of HCV+ cells
as a function of time was determined at 3–4 day intervals. Cells were
subjected to staining with anti-NS3 antibodies and analysis by flow
cytometry as described in the Materials and Methods.
doi:10.1371/journal.pone.0035351.g005
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suggest that properties, other than an effect on viral entry, (e.g.
virus assembly and release) may be responsible for the reduced
fitness and low frequency of these specific amino acid polymorph-
isms in the natural HCV genotype 1 population [47].
Tofurtherevaluatetherelativefitnessofthesepolymorphisms,we
successfully introduced each amino acid variant into the full-length
HCV GT 1b/2a reporter construct by site-directed mutagenesis.
WealsosuccessfullyintroducedV719GandV719AintotheGT1a/
2a HCV background, but were unable to generate stable clones
representing V719I and V719L in this background. Full-length
reporter RNA transcripts were prepared, purified and electro-
poratedintotargetcells.Viralsupernatantsweresampledevery3–4
days from long term HCV cell cultures. Growth kinetics were
determined by quantification of Renilla luciferase activity following
a 72 hr infection of naı ¨ve target cells with supernatants harvested
from long-term HCV cell cultures.
Following electroporation of naı ¨ve target cells, GT 1a/2a HCV
cell cultures displayed high levels of infectivity which gradually
increased over time out to 76 days in culture (Figure 7A). GT 1b/
2a HCV experienced a more rapid increase in Renilla luciferase
activity reaching peak levels at day 10 and then tapering off over
the following 66 days in culture (Figure 7C). The bell shaped
kinetics of the GT 1b/2a HCV infection was consistent with those
observed previously by others and published elsewhere [35].
Introduction of all natural and drug-induced polymorphisms into
either of the GT 1a/2a or GT 1b/2a HCV backgrounds resulted
in a marked reduction in viral infectivity as measured by Renilla
luciferase gene expression at day 10. The effect on viral infectivity
in culture ranged from a modest 6-fold inhibition, observed for
GT 1b/2a-V719I (Figure 7D), representing the most common
polymorphism, to a .2 log reduction in viral infectivity observed
for both the GT 1a/2a-V719G (Figure 7A) and GT 1b/2a-V719G
HCV cell cultures (Figure 7C). Taken together, the kinetics of
HCV infection in culture suggests that amino acid substitutions at
position 719 result in a significant decrease in viral fitness. Further
experiments, however, are required to fully understand the
mechanism and fitness costs of these amino substitutions at
position 719.
Several cultures exhibited low level infectivity for several weeks
in culture and then experienced a burst in Renilla luciferase
activity: GT 1a/2a-V719A (at day 37) (Figure 7B), and GT 1b/2a-
V719G (at day 43) (Figure 7C). Sequencing of the envelope
glycoproteins from these cultures revealed the presence of
additional amino acid substitutions within the E1 and E2
glycoproteins. All other viruses exhibited no change across the
E1/E2 envelope sequence, with the exception of GT 1b/2a-V719I
which had accumulated two additional substitutions within the
envelope sequence at day 10 (see Table S1). Further studies are
needed to determine whether these amino acid variants represent
adaptive or compensatory mutations or are simply the result of
genetic drift in the long-term HCV cell cultures.
Drug resistance properties of variant envelopes bearing
natural polymorphisms
The susceptibility of each potential variant envelope to
PRO0371155 was determined in the HCVpp assay. Compared
to the parent GT1a envelope, PRO0371155 was 500-fold less
active against the V719L variant in the HCVpp assay (Table 3,
compare EC50=2 nM (GT1a) to EC50 .1,000 nM GT1a-
V719L). This level of resistance was similar to that observed for
the V719G variant which was selected under drug pressure.
Introduction of either V719I or V719A into the GT 1a envelope
resulted in a more modest reduction in the potency of
PRO0371155 of 34- and 46-fold respectively (Table 3).
Isoleucine is the most common natural polymorphism and
represents a significant fraction of the genotype 1b sequences in
the public database (21%). Interestingly, the V719I substitution
had no effect on sensitivity to PRO0502797 in either the genotype
1a or 1b backgrounds (Table 3). In contrast, V719L exhibited
a significant reduction in sensitivity to PRO0502797 when
introduced into the genotype 1a background (Table 3) and a more
Table 2. V719G is sufficient to confer resistance to representative triazines in the HCVpp assay.
Cmpd. ID GT1a (EC50) GT1a Pass. Ctrl. (EC50) T388A (EC50) V719G (EC50)
JS-81 41 ng/mL 34 ng/mL 67 ng/mL 33 ng/mL
PRO0371155 2 nM 4 nM 2 nM .1,000 nM
PRO0502797 5 nM n/d n/d .1,000 nM
doi:10.1371/journal.pone.0035351.t002
Figure 6. Fusogenic properties of variant envelopes and
sensitivity to representative triazines in the HCVpp assay.
Individual variants, representing both drug-selected and natural
polymorphisms, were introduced by site directed mutagenesis of
plasmid vectors that express either the genotype 1a or 1b E1/E2
glycoproteins. Unique HCVpp, representing each variant were pro-
duced in 293T cells and normalized by p24 ELISA assay. Viral entry was
measured by quantifying luciferase activity as described in the Materials
and Methods. Luciferase activity was expressed as R.L.U. per nanogram
of p24. Cell lysates were prepared from 293T cells that were previously
co-transfected with envelope expression constructs and the HIV-1
vector. After normalizing for total protein content, proteins were then
separated by electrophoresis through an SDS-polyacrylamide gel and
subjected to western blot analysis with PA-25, a mouse monoclonal
antibody raised against sE2 derived from a genotype 1a strain.
doi:10.1371/journal.pone.0035351.g006
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background (Table 3). Likewise, introduction of V719A into either
of the genotype 1 backgrounds resulted in a modest reduction in
sensitivity to PRO0502797 (Table 3). The overall frequency of
pre-existing drug resistant polymorphisms in the HCV genotype 1
population is very low. Only I719 represents a significant fraction
of sequences in the genotype 1b background and this variant is
fully susceptible to inhibition by PRO0502797.
Discussion
We have completed a hit finding campaign against a random
library of diversified drug-like compounds and identified a series of
1,3,5-triazines, similar to that previously reported by Baldick and
co-workers [31]. In the Baldick study, a genotype 1b specific
primary screen led to the identification of hit compounds that were
highly specific for HCV genotype 1b strains. In a complementary
approach, we utilized a genotype 1a-based screen which led to the
discovery of compounds that were exclusively active against HCV
genotype 1a. Independent chemical optimization of these two
series produced triazine compounds that are broadly active against
both genotype 1a and 1b HCV strains. Further optimization
efforts were unable to uncover inhibitors that were broadly active
against other genotypes. Our studies provide an important
independent confirmation of the major anti-viral properties and
resistance patterns of the triazine series. We have extended
previous findings through the analysis of the relative fitness of
natural and drug-induced amino acid variants at position 719. We
show that the most common natural polymorphism, I719, remains
fully susceptible to inhibition by triazine inhibitors and that the
frequency of pre-existing, naturally resistant HCV variants is
extremely low in the genotype 1 background. We also demon-
strate, for the first time, that a highly active entry inhibitor can
lead to the eradication of an active HCV infection in cell culture.
HCV replication inhibitors have shown the ability to completely
suppress viral replication, leading to viral clearance in multiple
experimental systems including replicon cell lines [40,48]. Unlike
Figure 7. Effect of drug-induced and natural amino acid variants at position 719 on the growth kinetics of HCV genotype 1/2a in
cell culture. The drug resistant variant, V719G and three natural amino acid polymorphisms, I719, L719, A719, were introduced into genotype 1a
and 1b genetic backgrounds using the QuikChange II XL site-directed mutagenesis kit (Stratagene). Full-length HCV RNAs bearing various
polymorphisms at position 719 were prepared and electroporated into naı ¨ve target cells. Infected cell cultures were maintained for up to 2.5 months.
Every 3–4 days, viral supernatants were harvested and subsequently used to infect naı ¨ve target cells. After 72 hrs, Renilla luciferase activity was
measured and viral titer/infectivity was expressed in R.L.U. (relative light units). Changes in viral titers were plotted on a logarithmic scale as a function
of time. (A) A comparison of the growth kinetics of GT 1a/2a HCV (diamonds) with the drug-induced variant, GT 1a/2a-V719G (squares) (B) A
comparison of the growth kinetics of GT 1a/2a HCV (diamonds) with a potential polymorphism, GT 1a/2a-V719A (triangles). (C) A comparison of the
growth kinetics of GT 1b/2a HCV (diamonds) with the drug-induced polymorphism, GT 1b/2a-V719G (squares). (D) A comparison of the growth
kinetics of GT 1b/2a HCV (diamonds) with a natural polymorphism, GT 1b/2a-V719I (circles) and two potential polymorphisms GT 1b/2a-V719L
(squares) and GT 1b/2a-V719A (triangles).
doi:10.1371/journal.pone.0035351.g007
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protein expression was not expected in our studies since infected
cells should continue to produce viral particles in the presence of
an entry inhibitor. As expected, a slower rate of HCV+ cell decline
was observed in the PRO0371155 treated HCV cell cultures
compared with the INF-alpha treated control. However, it was
surprising to observe the complete clearance of HCV from
infected cell cultures over a relatively short duration in the
presence of an entry inhibitor alone. Although the mechanisms
that drive turnover of infected hepatocytes are not fully un-
derstood, induction of apoptotic pathways has recently been
observed in a chimeric mouse model of HCV infection [45,49]
and later confirmed in the HCV cell culture system with human
hepatoma-derived cell lines [44]. The dynamics of HCV infection
in culture suggest a model in which infected cells continually
turnover due to apoptotic mechanisms. Consistent with this model,
HCV cell cultures treated with PRO0371155 grew more
efficiently and exhibited less cell death compared to untreated
control cultures (data not shown). Our results suggest that multiple
rounds of infection of naı ¨ve hepatocytes are likely required to
maintain HCV infection in culture and, presumably, in vivo.
In a normal healthy liver, the rates of hepatocyte proliferation
and cell death are negligible. As a result, hepatocytes are long lived
and exhibit minimal turnover in vivo (T1/2,70 days). In patients
chronically infected with HCV, however, the proportion of
proliferating hepatocytes increases dramatically by 100- to
1,400-fold compared to healthy controls, as determined by
staining of biopsies for cell division markers [50]. Fitting patient
data to mathematical models that take into account hepatocyte
proliferation also suggests that during anti-viral therapy, pro-
ductively infected cells are preferentially replaced by proliferating
naı ¨ve, non-infected hepatocytes [43]. Although our in vitro system
is incomplete, the observed viral dynamics in cell culture provides
some experimental support for this hypothesis. In the presence of
inhibitory concentrations of PRO0371155, the rate of infection
approaches zero. Under these conditions, non-infected naı ¨ve cells
proliferate and eventually dominate the cell culture population.
The implications of these results are two-fold: 1) HCV infected
cells die at a faster rate than non-infected cells in culture and 2)
HCV infected cells proliferate at a slower rate than non-infected
cells in culture. A contrasting picture is observed in control
cultures that lack PRO0371155. In this case, the rate of infection
of naı ¨ve target cells is greater than the rate of cell death of
productively infected cells. As a result, HCV spreads rapidly to
infect nearly 90% of the cells in culture. Moreover, these cell
cultures remain stably infected over multiple months. Our results
demonstrate that long term exposure to a potent entry inhibitor
can lead to the eradication of HCV in vitro.
To date, only one oral HCV entry inhibitor with a defined
mechanism of action, ITX-5061 (iTherX), has entered clinical
testing (Phase 2a) [51]. ITX-5061 binds directly to SR-B1, a known
HCV co-receptor, and blocks a key post-binding step in the viral
entry process [51]. Preliminary mechanism of action studies
indicate that the triazines also target the HCV envelope at a post-
attachment step in the entry process (data not shown). However,
triazines do not block binding of soluble E2 to cell lines expressing
CD81 and/or SR-B1 in neutralization of binding experiments
(data not shown). The triazine series, therefore, exhibits a distinct
mechanism of action compared to ITX-5061 and is likely to
possess a complementary pattern of resistance. Our drug resistance
studies directly implicate the transmembrane domain of E2 as
a potential target for the triazine series. The partially buried
location of V719 near the surface of the viral membrane fuels
speculation that the triazines may interfere with HCV fusion.
Further studies are required to test this hypothesis and to fully
define the molecular target and mechanism of action of this
inhibitor series.
PreviousmodelsofHCVviraldynamicshaveprovidedimportant
information into ribavirin’s mechanism of action and contribution
tocombinationtherapywithpegylatedinterferon-alpha[52].These
modelsmayalsoprovideimportantinsightsintothepotentialroleof
an entry inhibitor in a future combination therapy for HCV
infection. Therapeutic interventionwithpegylated interferon-alpha
typically results ina biphasic pattern of HCV RNA decay [46]. The
first phase of viral decay represents the rapid clearance of HCV
particles from the plasma compartment following inhibition of
replication. The second, slower phase is governed by the rate of
infectedhepatocytecelldeath,counterbalancedbytherateofdenovo
infection and the rate of proliferation of productively infected cells
[46,53].Ribavirin hasbeenshownto acceleratethesecondphase of
viral decay in a dose-dependent manner when the response to
pegylated interferon-alpha is low [52]. Although mechanistically
distinct from ribavirin, entry inhibitors would be expected to
similarlyaffectthesecondphaseofHCVdecaybyvirtueofblocking
new rounds of HCV infection [43,52]. Models of HCV viral
dynamics support the addition of an entry inhibitor to HCV
combination therapy to improve SVR rates and prevent the
establishment and outgrowth of drug-resistant viruses in a manner
similar to that observed for ribavirin.
Newanti-viraldrugs,withcomplementarymechanismsofaction,
are needed to reliably cure patients of HCV infection and to reduce
the toxicity and duration of treatment. Viral entry is a validated
target for other highly mutable viruses and represents a novel and
Table 3. Natural polymorphisms at position 719 confer resistance to representative triazines in the HCVpp assay.
Background Envelope JS-81 (EC50) PRO0371155 (EC50) PRO0502797 (EC50)
Genotype 1a GT 1a 48 ng/mL 2 nM 5 nM
V719L 97 ng/mL .1,000 nM (5006) 625 nM (1256)
V719I 62 ng/mL 67 nM (346) 5 nM (16)
V719A 53 ng/mL 92 nM (466)3 5 n M ( 7 6)
Genotype 1b GT 1b 50 ng/mL 317 nM 3 nM
V719L 41 ng/mL .1,000 nM (36)2 7 n M ( 9 6)
V719I 78 ng/mL .1,000 nM (36) 3 nM (16)
V719A 30 ng/mL 273 nM (0.96)1 2 n M ( 4 6)
doi:10.1371/journal.pone.0035351.t003
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and optimized a series of triazine compounds that are potent,
selective and non-cytotoxic inhibitors of HCV entry. Compounds
from this series have demonstrated high anti-viral activity against
HCV in vitro, including the ability to eradicate HCV from infected
cell cultures. These findings support further investigation of entry
inhibitors as a potential new class for HCV therapy.
Supporting Information
Table S1 HCV cell cultures representing various drug-induced
and natural amino acid polymorphisms were established as
described in the legend to Figure 7. Once peak viral titers were
achieved, HCV RNA was isolated from each culture and the E1/
E2 glycoprotein coding sequence was amplified by RT-PCR and
subjected to direct DNA sequencing. Amino acid substitutions
identified in the E1 or E2 glycoproteins are summarized in Table
S1. The time to peak titers and associated sequencing data are also
denoted in Table S1. Following electroporation of naı ¨ve target
cells, GT 1a/2a-V719A HCV initially exhibited 1–2 log lower
Renilla luciferase activity compared to the parent GT 1a/2a HCV
background. At day 40, however, the GT 1a-V719A HCV cell
culture experienced a burst in luciferase activity. Sequencing of the
E1/E2 envelope glycoproteins from day 76 cultures revealed the
presence of one additional amino acid variant, D263E which is
localized to the N-terminal region of a hydrophobic domain in E1
(aa262–290) that houses a putative fusion peptide sequence. No
changes were observed in the E1/E2 envelope sequences from
either the parent GT 1a/2a HCV or the GT 1a/2a-V719G HCV
variant cultures as determined by sequencing of day 69 and 76
cultures, respectively. In contrast to the GT 1a/2a HCV cell
culture, the parent GT 1b/2a HCV showed a distinct pattern of
infectivity in cell culture. In this case, Renilla luciferase activity
rapidly reached a maximum level at day 9–10, tapering off over
the following 67 days in culture. The GT 1b/2a-V719I and GT
1b/2a-V719G HCV variants exhibited 6- and 20-fold reduced
levels of Renilla luciferase activity compared to the parent GT 1b/
2a HCV background, respectively, while the GT 1b/2a-V719G
and GT 1b/2a-V719L HCV variants exhibited a more dramatic,
2–3 log, reduction in viral titers. Sequencing of day 10 cultures
revealed the presence of two additional amino acid variations in
the GT 1b/2a-V719I HCV sequence. One substitution, A357T,
was localized to the transmembrane domain of E1 (aa353–381)
while the second substitution, A746P, was located at the
immediate C-terminus of the E2 protein near the transmembrane
domain. No other changes were identified by sequencing of the
GT 1b/2a-V719L (day 51), GT 1b/2a-V719A HCV (day 9)
variants or the parent GT 1b/2a HCV background (day 9). The
GT 1b/2a-V719G HCV variant exhibited low levels of infectivity
compared to the parent GT 1b/2a HCV at day 9–10. A
significant burst in Renilla luciferase activity was observed
between days 43–50. Sequencing at day 69 revealed two
additional amino acid substitutions including: A217E and
A457G located in the E1 and E2 glycoproteins, respectively.
Surprisingly, viral titers of HCV GT 1b/2a reporter constructs
bearing these amino acid substitutions reached and surpassed the
peak levels observed for the parental GT1 b/2a HCV strain.
Additional experiments are necessary to determine whether these
amino acid variants represent adaptive or compensatory mutations
or are simply the result of genetic drift in the long-term HCV cell
cultures. Moreover, the potential role of these amino acid positions
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